ArticleMarine biotechnology (New York, N.Y.)2025
Optimizing Extracellular Products from Vibrio proteolyticus for Their Use as Postbiotics in Aquaculture.
Article in Marine biotechnology (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Vibrio proteolyticus DCF12.2 has demonstrated its ability to be used as a probiotic for fish species. This study investigates how different culture conditions influence the activity of its extracellular products (ECPs) in aquaculture, focusing on enzymatic and antibacterial activity, cytotoxicity, biofilm modulation, short-chain fatty acid (SCFA) profiles, and effects on Photobacterium damselae subsp. piscicida virulence. Enzymatic assays showed a variety of hydrolytic activities, including amylase, caseinase, and collagenase, which can enhance digestion and nutrient absorption in fish. Antibacterial assays revealed that ECPs from V. proteolyticus grown in an experimental aquafeed and a partial replacement of that aquafeed by 25% of a blend of microalgae inhibited P. damselae subsp. piscicida and P. damselae subsp. damselae. Cytotoxicity assays indicated variable effects across fish cell lines, with increased viability in SAF-1 and DLB-1 cells under specific conditions, and decreased viability in PLHC-1 cells, suggesting potential antitumor properties. Biofilm assays showed that certain ECP conditions reduced biofilm formation by Vibrio anguillarum, Aeromonas hydrophila, and Tenacibaculum maritimum. SCFA profiling detected acetic, iso-valeric, butyric, and valeric acids, which may contribute to antimicrobial activity and gut health. The ECPs significantly downregulated aip56 gene transcription, reducing the virulence of P. damselae subsp. piscicida. These findings suggest that ECPs from V. proteolyticus could be valuable aquafeed additives for enhancing fish nutrition, health, and disease resistance. Future research should aim to isolate and characterize the specific bioactive compounds responsible for these effects and elucidate their mechanisms of action for optimized application in aquaculture and other biotechnological fields.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.